Associated Genetic Biomarkers
TNFRSF13C status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains TNFRSF13C status as an inclusion criterion, 1 is phase 1 (0 open).
Trials with TNFRSF13C status in the inclusion eligibility criteria most commonly target B-cell acute lymphoblastic leukemia .
The most frequent alteration to serve as an inclusion eligibility criterion is TNFRSF13C Expression .
Baffr-car t cells is the most frequent therapy in trials with TNFRSF13C as an inclusion criteria .
Significance of TNFRSF13C in Diseases
B-Cell Acute Lymphoblastic Leukemia +
TNFRSF13C is an inclusion criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 0 are open and 1 is closed. Of the trial that contains TNFRSF13C status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.